Zhaoke Ophthalmology-B (06622) saw its shares surge more than 7% during the trading session. As of the time of writing, the stock was up 3.44%, trading at HK$3.61, with a turnover of HK$11.43 million.

On January 26, Zhaoke Ophthalmology announced it has granted exclusive commercialization rights for its core presbyopia treatment drug, BRIMOCHOL™ PF, in Singapore and Vietnam to New Zealand's AFT Pharmaceuticals and Japan's Senju Pharmaceutical, respectively.

This move extends Zhaoke Ophthalmology's global commercial footprint to eight markets: South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan, Singapore, and Vietnam.

Under the agreements, Zhaoke Ophthalmology has granted AFT exclusive distribution rights in Singapore and Senju exclusive distribution rights in Vietnam.

AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company whose core business model focuses on developing and licensing products in over 125 countries worldwide.

Senju Pharmaceutical is a research-driven private Japanese pharmaceutical company with years of specialization in the ophthalmology field, aiming to enhance global patients' vision health through original medications.